Understanding Deshi Technology (02526) Mid-term Performance for 2026: Entering a New Stage of the "Medical Imaging AI Research and Production Acceleration Platform"

On August 7, DIAGENS-B (02526) released its 2026 interim results, showing that during the reporting period, the company achieved total operating revenue of approximately 109 million yuan, of which modeling service revenue was 95 million yuan, a year-on-year increase of 101.1%; the share of modeling services in total revenue increased to 86.9%, further enhancing the medical AI commercialization capability. During the period, the company increased its investment in underlying research and development, with R&D investment growing 67.4% year-on-year.